A phase 1 study on midostaurin plus panobinostat in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome

Introduction: Midostaurin is a non-specific FLT3 inhibitor that showed anti-leukemic activity against both FLT3 mutated as well as unmutated Acute Myeloid Leukemia (AML) in early phase studies. Panobinostat, a potent oral pan-acetylase inhibitor had also shown significant anti-leukemic signals in early phase studies. In the preclinical study, our group had previously reported synergistic anti-leukemic activity when an FLT3 inhibitor was used in...